218 related articles for article (PubMed ID: 24400596)
1. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
Bonner-Weir S; In't Veld PA; Weir GC
Diabetes Obes Metab; 2014 Jul; 16(7):661-6. PubMed ID: 24400596
[TBL] [Abstract][Full Text] [Related]
2. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
Diabetes; 2013 Jul; 62(7):2595-604. PubMed ID: 23524641
[TBL] [Abstract][Full Text] [Related]
3. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Engel SS; Golm GT; Lauring B
Diabetes; 2013 Oct; 62(10):e18. PubMed ID: 24065799
[No Abstract] [Full Text] [Related]
4. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Heine RJ; Fu H; Kendall DM; Moller DE
Diabetes; 2013 Oct; 62(10):e16-7. PubMed ID: 24065798
[No Abstract] [Full Text] [Related]
5. Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
Diabetes; 2013 Oct; 62(10):e19-22. PubMed ID: 24065800
[No Abstract] [Full Text] [Related]
6. Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
Cox AR; Lam CJ; Rankin MM; Rios JS; Chavez J; Bonnyman CW; King KB; Wells RA; Anthony D; Tu JX; Kim JJ; Li C; Kushner JA
Endocrinology; 2017 Jun; 158(6):1701-1714. PubMed ID: 28323942
[TBL] [Abstract][Full Text] [Related]
7. Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Ueberberg S; Jütte H; Uhl W; Schmidt W; Nauck M; Montanya E; Tannapfel A; Meier J
Diabetes Obes Metab; 2016 Dec; 18(12):1253-1262. PubMed ID: 27545110
[TBL] [Abstract][Full Text] [Related]
8. Incretin therapy and islet pathology: a time for caution.
Kahn SE
Diabetes; 2013 Jul; 62(7):2178-80. PubMed ID: 23596147
[No Abstract] [Full Text] [Related]
9. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
10. Lipotoxicity impairs incretin signalling.
Poitout V
Diabetologia; 2013 Feb; 56(2):231-3. PubMed ID: 23188391
[TBL] [Abstract][Full Text] [Related]
11. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Harja E; Lord J; Skyler JS
Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
[TBL] [Abstract][Full Text] [Related]
12. The role of incretin on diabetes mellitus.
Sanusi H
Acta Med Indones; 2009 Oct; 41(4):205-12. PubMed ID: 20737753
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based therapy and pancreatic beta cells.
Chon S; Riveline JP; Blondeau B; Gautier JF
Diabetes Metab; 2014 Dec; 40(6):411-22. PubMed ID: 25443548
[TBL] [Abstract][Full Text] [Related]
14. The impact of diabetic autonomic neuropathy on the incretin effect.
Kazakos KA; Sarafidis PA; Yovos JG
Med Sci Monit; 2008 Apr; 14(4):CR213-20. PubMed ID: 18376350
[TBL] [Abstract][Full Text] [Related]
15. Novo Nordisk incretin leadership summit, Cape Town.
Cardiovasc J Afr; 2012 Jun; 23(5):288-92. PubMed ID: 23077732
[No Abstract] [Full Text] [Related]
16. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.
Salehi M; Aulinger BA; D'Alessio DA
Endocr Rev; 2008 May; 29(3):367-79. PubMed ID: 18292465
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
Nauck M; Smith U
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):513-23. PubMed ID: 19748068
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
Nauck MA
Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
[TBL] [Abstract][Full Text] [Related]
19. Promising Diabetes Therapy Based on the Molecular Mechanism for Glucose Toxicity: Usefulness of SGLT2 Inhibitors as well as Incretin-Related Drugs.
Kaneto H; Obata A; Shimoda M; Kimura T; Hirukawa H; Okauchi S; Matsuoka TA; Kaku K
Curr Med Chem; 2016; 23(27):3044-3051. PubMed ID: 27356542
[TBL] [Abstract][Full Text] [Related]
20. Incretin hormones and beta cell function in chronic pancreatitis.
Knop FK
Dan Med Bull; 2010 Jul; 57(7):B4163. PubMed ID: 20591345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
